There has been a raft of good news this week regarding the COVID-19 pandemic. First off, on 9 November, Pfizer (NYSE: PFE), along with German biotechnology company BioNTech, announced interim results on its vaccine candidate that showed a 90% efficacy rate. Of the 44,000 volunteers who participated in the vaccine trial, data shows that more people who received the placebo developed COVID-19, versus those who received the actual vaccine. Recently just two days ago, Moderna Therapeutics (NASDAQ: MRNA) announced that its vaccine candidate achieved an even higher efficacy rate of 94.5% against the dreaded disease. For many, these two pieces of news are like a breath of fresh air after a tough year. But there are still significant challenges to delivering these vaccines to the general populace. For one, transportation and storage are a challenge as Pfizer’s vaccine needs to be kept at minus 70 degrees Celsius and can only last up to five days with refrigeration....